Maresin 1 Alleviates Diabetic Kidney Disease via LGR6-Mediated cAMP-SOD2-ROS Pathway.
Animals
Antioxidants
Diabetes Mellitus, Experimental
/ metabolism
Diabetes Mellitus, Type 2
/ complications
Diabetic Nephropathies
/ metabolism
Docosahexaenoic Acids
Female
Glucose
Humans
Hyperglycemia
/ complications
Inflammation
Male
Mice
Mice, Inbred C57BL
Reactive Oxygen Species
Receptors, G-Protein-Coupled
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
11
2021
revised:
11
03
2022
accepted:
23
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Chronic hyperglycemia-induced inflammation is recognized as the most important pathophysiological process in diabetic kidney disease (DKD). As maresin 1 (MaR1) is an extensive anti-inflammatory lipid mediator, the present study investigated the protective role of MaR1 in the pathogenesis of DKD and its clinical relevance. Serum MaR1 concentrations were analyzed in 104 subjects with normal glucose tolerant, type 2 diabetes (T2DM), or DKD. Streptozotocin (STZ) together with high fat diet was used to induce male C57BL/6 J mice into diabetic mice which were treated with MaR1. Human renal tubule epithelial cells (HK-2 cells) were treated by high glucose for glucotoxicity cell model and transfected with LGR6 siRNA for knockdown with MaR1 added，and detected oxidative stress and inflammatory related factors. Serum MaR1 concentrations were significant decreased in T2DM with or without kidney disease compared with normal participant and were lowest in patients with DKD. Serum MaR1 concentrations were negatively correlated with hemoglobin A1c (HbA1c), duration of diabetes, urinary albumin to creatinine ratio (UACR), neutrophil, and neutrophil-lymphocyte ratio and were positively correlated with high-density lipoprotein-cholesterol (HDL-C) and estimated glomerular filtration rate (eGFR). In mouse model, MaR1 injection alleviated hyperglycemia, UACR and the pathological progression of DKD. Interestingly, the renal expression of LGR6 was down-regulated in DKD and high glucose treated HK-2 cells but up-regulated by MaR1 treatment. Mechanistically, MaR1 alleviated inflammation via LGR6-mediated cAMP-SOD2 antioxidant pathway in DKD mice and high glucose treated HK-2 cells. Our study demonstrates that decreased serum MaR1 levels were correlated with the development of DKD. MaR1 could alleviate DKD and glucotoxicity-induced inflammation via LGR6-mediated cAMP-SOD2 antioxidant pathway. Thus, our present findings identify MaR1 as a predictor and a potential therapeutic target for DKD.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic hyperglycemia-induced inflammation is recognized as the most important pathophysiological process in diabetic kidney disease (DKD). As maresin 1 (MaR1) is an extensive anti-inflammatory lipid mediator, the present study investigated the protective role of MaR1 in the pathogenesis of DKD and its clinical relevance.
METHODS
METHODS
Serum MaR1 concentrations were analyzed in 104 subjects with normal glucose tolerant, type 2 diabetes (T2DM), or DKD. Streptozotocin (STZ) together with high fat diet was used to induce male C57BL/6 J mice into diabetic mice which were treated with MaR1. Human renal tubule epithelial cells (HK-2 cells) were treated by high glucose for glucotoxicity cell model and transfected with LGR6 siRNA for knockdown with MaR1 added，and detected oxidative stress and inflammatory related factors.
RESULTS
RESULTS
Serum MaR1 concentrations were significant decreased in T2DM with or without kidney disease compared with normal participant and were lowest in patients with DKD. Serum MaR1 concentrations were negatively correlated with hemoglobin A1c (HbA1c), duration of diabetes, urinary albumin to creatinine ratio (UACR), neutrophil, and neutrophil-lymphocyte ratio and were positively correlated with high-density lipoprotein-cholesterol (HDL-C) and estimated glomerular filtration rate (eGFR). In mouse model, MaR1 injection alleviated hyperglycemia, UACR and the pathological progression of DKD. Interestingly, the renal expression of LGR6 was down-regulated in DKD and high glucose treated HK-2 cells but up-regulated by MaR1 treatment. Mechanistically, MaR1 alleviated inflammation via LGR6-mediated cAMP-SOD2 antioxidant pathway in DKD mice and high glucose treated HK-2 cells.
CONCLUSIONS
CONCLUSIONS
Our study demonstrates that decreased serum MaR1 levels were correlated with the development of DKD. MaR1 could alleviate DKD and glucotoxicity-induced inflammation via LGR6-mediated cAMP-SOD2 antioxidant pathway. Thus, our present findings identify MaR1 as a predictor and a potential therapeutic target for DKD.
Identifiants
pubmed: 35498124
doi: 10.1155/2022/7177889
pmc: PMC9042615
doi:
Substances chimiques
7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid
0
Antioxidants
0
LGR6 protein, human
0
Lgr6 protein, mouse
0
Reactive Oxygen Species
0
Receptors, G-Protein-Coupled
0
Docosahexaenoic Acids
25167-62-8
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7177889Informations de copyright
Copyright © 2022 Xinyue Li et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Pharmacol Res. 2019 Sep;147:104391
pubmed: 31401210
Biomed Res Int. 2013;2013:125469
pubmed: 24089659
Hum Reprod. 2002 Jul;17(7):1709-14
pubmed: 12093828
Front Cell Dev Biol. 2021 Jul 12;9:696542
pubmed: 34327204
Mol Metab. 2019 Dec;30:250-263
pubmed: 31767176
Eur J Pharmacol. 2007 Jul 30;568(1-3):242-7
pubmed: 17511984
JAMA. 2015 Sep 1;314(9):884-94
pubmed: 26325557
Medicine (Baltimore). 2021 Jul 30;100(30):e26431
pubmed: 34397684
J Am Heart Assoc. 2021 Aug 3;10(15):e019437
pubmed: 34308664
Mol Endocrinol. 2005 Apr;19(4):1067-77
pubmed: 15650020
Int J Mol Sci. 2019 Jul 10;20(14):
pubmed: 31295940
Front Endocrinol (Lausanne). 2013 Feb 06;4:7
pubmed: 23390421
Int J Obes (Lond). 2018 Mar;42(3):572-579
pubmed: 28895586
Antioxid Redox Signal. 2016 Oct 20;25(12):657-684
pubmed: 26906673
Int J Mol Sci. 2019 Nov 21;20(23):
pubmed: 31766461
Diabetes Obes Metab. 2017 Nov;19(11):1610-1619
pubmed: 28636754
Mediators Inflamm. 2020 Apr 16;2020:4539035
pubmed: 32377160
Prim Care Diabetes. 2021 Apr;15(2):208-211
pubmed: 32912710
PLoS One. 2012;7(5):e37137
pubmed: 22615920
Expert Opin Drug Discov. 2021 Apr;16(4):447-461
pubmed: 33003971
Front Pharmacol. 2020 Dec 21;11:586892
pubmed: 33519447
Hypertension. 2020 Dec;76(6):1935-1944
pubmed: 33131311
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1715-1727
pubmed: 33239409
Cochrane Database Syst Rev. 2021 Oct 25;10:CD013650
pubmed: 34693515
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13249-54
pubmed: 26460010
Oxid Med Cell Longev. 2021 Feb 17;2021:6691226
pubmed: 33680286
Expert Opin Ther Targets. 2019 Jul;23(7):579-591
pubmed: 31154867
Lab Invest. 2018 Jun;98(6):715-733
pubmed: 29467458
Am J Kidney Dis. 2015 Sep;66(3):441-9
pubmed: 25960304
Oxid Med Cell Longev. 2018 Nov 13;2018:2976957
pubmed: 30538800
Clin Sci (Lond). 2009 Mar;116(6):479-92
pubmed: 19200057
Nat Commun. 2021 Apr 22;12(1):2368
pubmed: 33888696
Prog Lipid Res. 2020 Apr;78:101034
pubmed: 32360520
DNA Cell Biol. 2017 Apr;36(4):249-255
pubmed: 28151018
Biochem Biophys Res Commun. 2019 Oct 29;519(1):1-7
pubmed: 31500806
J Physiol Biochem. 2021 Feb;77(1):167-173
pubmed: 33206345
Drug Des Devel Ther. 2019 Feb 20;13:739-745
pubmed: 30863013
Indian J Endocrinol Metab. 2017 May-Jun;21(3):387-392
pubmed: 28553592
Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7442-7453
pubmed: 32706084
Diabetol Metab Syndr. 2022 Jan 4;14(1):2
pubmed: 34983623
Diabetes. 2008 Mar;57(3):714-23
pubmed: 18083785
Nat Rev Nephrol. 2020 Apr;16(4):206-222
pubmed: 31942046
Cell Metab. 2010 Dec 1;12(6):662-7
pubmed: 21109198
Diabetes Care. 2013 Nov;36(11):3460-8
pubmed: 24026560
JAMA. 2019 Jan 1;321(1):69-79
pubmed: 30418475
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F716-F731
pubmed: 27558558
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Rev Med Chir Soc Med Nat Iasi. 2009 Apr-Jun;113(2):363-70
pubmed: 21491818
Plast Reconstr Surg. 2016 Feb;137(2):495-507
pubmed: 26818284
Sci Rep. 2018 Apr 13;8(1):5958
pubmed: 29654303
Diabetes Care. 2004 Jan;27 Suppl 1:S11-4
pubmed: 14693922
Exp Cell Res. 2012 May 15;318(9):986-92
pubmed: 22414874
Br J Pharmacol. 2020 Aug;177(16):3691-3711
pubmed: 32352559
BMJ. 2021 Jan 13;372:m4573
pubmed: 33441402
Cardiovasc Drugs Ther. 2017 Dec;31(5-6):579-592
pubmed: 28956186
Oxid Med Cell Longev. 2019 Nov 28;2019:5681701
pubmed: 31871550
J Korean Med Sci. 2020 Sep 14;35(36):e305
pubmed: 32924342
J Immunol. 2013 Oct 15;191(8):4288-98
pubmed: 24038091
Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154
pubmed: 17276798
Theranostics. 2019 May 31;9(15):4287-4307
pubmed: 31285762
J Clin Invest. 1997 Aug 1;100(3):671-7
pubmed: 9239415
J Clin Invest. 2019 Dec 2;129(12):5294-5311
pubmed: 31657786
J Biol Chem. 1993 Oct 25;268(30):22243-6
pubmed: 8226728
J Immunol. 2010 Jan 15;184(2):836-43
pubmed: 20007539
J Endocrinol Invest. 2013 Sep;36(8):593-9
pubmed: 23511196
Int Immunopharmacol. 2019 Apr;69:103-108
pubmed: 30690344
Clin Endocrinol (Oxf). 2015 Feb;82(2):229-33
pubmed: 25088518
J Lipid Res. 2021;62:100120
pubmed: 34560080
FEBS Lett. 2001 Mar 16;492(3):199-203
pubmed: 11257494
Mediators Inflamm. 2017;2017:2438247
pubmed: 28182085
FASEB J. 2021 Aug;35(8):e21780
pubmed: 34320253
FASEB J. 2017 May;31(5):2135-2145
pubmed: 28188173
Curr Diab Rep. 2011 Aug;11(4):330-6
pubmed: 21557044